Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19935097 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL2292636 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL15260475 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL24531188 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL13671169 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL23618308 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL23133631 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL24822648 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL10261426 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL12648681 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018275-B2 | Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3626832-B1 | METHOD OF IDENTIFYING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4299741-A2 | DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS | The Broad Institute, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230399662-A1 | DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS | THE BROAD INSTITUTE, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| EP-4183876-A1 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR HBV AND VIRAL DISEASES AND DISORDERS | The Broad Institute, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11041173-B2 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications | THE BROAD INSTITUTE, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3825406-A1 | DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY | The Broad Institute Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3327127-B1 | DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS | BROAD INST INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200392541-A1 | DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY | THE BROAD INSTITUTE, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200389425-A1 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR HBV AND VIRAL DISEASES AND DISORDERS | THE BROAD INSTITUTE, INC. (US) | 2020-12-10 | — | — | US | disclosed |
| US-20090048410-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090023890-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-01-22 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287628-A1 | Endosomolytic Poly(Vinyl Ether) Polymers | Arrowhead Madison Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Pharmaceuticals, Inc. | 2008-06-26 | — | — | US | disclosed |
| WO-2008022309-A2 | POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | HDAC6, CD47, AADAC | MAPK1 3199/4885MEN1 932/4885KMT2A 2994/4885 |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, PCBP1, NCL | MAPK1 3493/4885MEN1 1697/4885KMT2A 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.